These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 15364332

  • 1. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis.
    Kaufman ES, Zimmermann PA, Wang T, Dennish GW, Barrell PD, Chandler ML, Greene HL, Atrial Fibrillation Follow-up Investigation of Rhythm Management investigators.
    J Am Coll Cardiol; 2004 Sep 15; 44(6):1276-82. PubMed ID: 15364332
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.
    Chung MK, Shemanski L, Sherman DG, Greene HL, Hogan DB, Kellen JC, Kim SG, Martin LW, Rosenberg Y, Wyse DG, AFFIRM Investigators.
    J Am Coll Cardiol; 2005 Nov 15; 46(10):1891-9. PubMed ID: 16286177
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M, Barrell P, AFFIRM Investigators.
    Am Heart J; 2005 Apr 15; 149(4):657-63. PubMed ID: 15990749
    [Abstract] [Full Text] [Related]

  • 7. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study).
    Freudenberger RS, Wilson AC, Kostis JB, AFFIRM Investigators and Committees.
    Am J Cardiol; 2007 Jul 15; 100(2):247-52. PubMed ID: 17631079
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN, CRAFT Investigators.
    J Am Coll Cardiol; 2004 Dec 21; 44(12):2355-61. PubMed ID: 15607398
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study.
    Curtis AB, Seals AA, Safford RE, Slater W, Tullo NG, Vidaillet H, Wilber DJ, Slee A.
    Am Heart J; 2005 Feb 21; 149(2):304-8. PubMed ID: 15846269
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysis.
    Choudhry NK, Zagorski B, Avorn J, Levin R, Sykora K, Laupacis A, Mamdani M.
    Ann Pharmacother; 2008 Nov 21; 42(11):1563-72. PubMed ID: 18827174
    [Abstract] [Full Text] [Related]

  • 16. Comparison of management patterns and clinical outcomes in patients with atrial fibrillation in Canada and the United States (from the analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] database).
    O'Hara GE, Charbonneau L, Chandler M, Vidaillet HJ, Philippon F, Sami M, Rocco TA, Padder FA, Champagne J, Pratt CM, Coutu B, Wyse DG, AFFIRM Investigators.
    Am J Cardiol; 2005 Sep 15; 96(6):815-21. PubMed ID: 16169368
    [Abstract] [Full Text] [Related]

  • 17. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up.
    Pezawas T, Stix G, Kastner J, Schneider B, Wolzt M, Schmidinger H.
    Int J Cardiol; 2006 Mar 08; 107(3):360-8. PubMed ID: 16503259
    [Abstract] [Full Text] [Related]

  • 18. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia.
    Shiga T, Tanaka K, Kato R, Amino M, Matsudo Y, Honda T, Sagara K, Takahashi A, Katoh T, Urashima M, Ogawa S, Takano T, Kasanuki H, Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators.
    Resuscitation; 2010 Jan 08; 81(1):47-52. PubMed ID: 19913983
    [Abstract] [Full Text] [Related]

  • 19. Rate control versus rhythm control.
    Vidaillet H, Greenlee RT.
    Curr Opin Cardiol; 2005 Jan 08; 20(1):15-20. PubMed ID: 15596954
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.